Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban by unknown
RESEARCH ARTICLE Open Access
Effects of thromboprophylaxis on
mesenchymal stromal cells during
osteogenic differentiation: an in-vitro study
comparing enoxaparin with rivaroxaban
Hakan Pilge1*†, Julia Fröbel1†, Silvia J. Mrotzek1†, Johannes C. Fischer2, Peter M. Prodinger3, Christoph Zilkens1,
Bernd Bittersohl1 and Rüdiger Krauspe1
Abstract
Background: Low-molecular-weight heparins (e.g. Enoxaparin) are widely used to prevent venous
thromboembolism after orthopaedic surgery, but there are reports about serious side effects including reduction
in bone density and strength. In recent years new oral antithrombotic drugs (e.g. direct Factor Xa-inhibitor,
Rivaroxaban) have been used to prevent venous thromboembolism. However, there is lack of information on the
effects of these new drugs on human mesenchymal stromal cells during osteogenic differentiation and, therefore,
effects during postoperative bone healing.
Methods: We evaluated the effects of Rivaroxaban and Enoxaparin on the proliferation, mRNA and surface receptor
expression as well as differentiation capacity of primary human mesenchymal stromal cells during their osteogenic
differentiation.
Results: Enoxaparin, but not Rivaroxaban treatment significantly increased human mesenchymal stromal cell
(hMSC) proliferation during the first week of osteogenic differentiation while suppressing osteogenic marker genes,
surface receptor expression and calcification.
Conclusions: This is the first paper to demonstrate that Rivaroxaban had no significant influence on hMSC
differentiation towards the osteogenic lineage, indicating a less affected bone healing process compared with
Enoxaparin in vitro. Based on these findings Rivaroxaban seems to be superior to Enoxaparin in early stages of
bone healing in vitro.
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Background
Following general and orthopaedic surgery, thrombopro-
phylaxis is essential to avoid venous thromboembolism
(VTE). Current treatment options for prevention include
heparin and low-molecular-weight heparins (LMWHs).
Without any prophylaxis, the risk of developing VTE after
major lower extremity orthopaedic surgery is between 40
and 60 % [1, 2]. With the use of Enoxaparin (a commonly
used LMWH), the risk can be reduced to 2 % [3].
After binding to antithrombin III (AT3), Enoxaparin
accelerates the activity of AT3 and potentiates the inhib-
ition of factors Xa and IIa. As factor Xa catalyzes the
conversion of prothrombin to thrombin, enoxaparin
decreases thrombin and therefore ultimately prevents
fibrin clot formation.
Until now, heparin and LMWHs have been the “gold
standard”, although there are reports about adverse
effects. Studies report that long-term administration
negatively affect postoperative bone healing, increase the
risk of fracture and of developing osteoporosis [4–7].
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In recent years oral “factor Xa inhibitor” drugs, e.g.
Rivaroxaban, have been used to prevent postoperative
VTE. These drugs act directly upon factor Xa in the co-
agulation cascade and inhibit both thrombin formation
and the development of thrombi and have no effect on
platelets [8]. With Rivaroxaban, the occurrence of major
VTE after hip arthroplasty was reduced to 0.2 % [3].
Furthermore, the incidence of major bleeding did
not differ significantly between patients treated with
Rivaroxaban (0.3 %) or Enoxaparin (0.1 %).
Enoxaparin was shown to inhibit cell proliferation at a
prophylactic dose [9] and it is assumed that LMWHs
alter the expression of cytokines (IL1, IL6, IL11 and
tumor necrosis factor-α (TNF-α)) that are necessary for
differentiation of MSCs into osteoblasts [10].
Interestingly, to date little is known about the cellular
effects of oral factor Xa inhibitors on the migration, pro-
liferation, differentiation and calcification of human
mesenchymal stromal cells (hMSC) and osteoblasts. In a
rat femur fracture model Rivaroxaban had no influence
on fracture healing as revealed by micro CT-scans and
biomechanical testing [11].
However, it is not known whether treatment with
Rivaroxaban modulates postoperative bone healing in
human patients. The aim of this study was to evaluate
the effects of both Rivaroxaban and Enoxaparin on
hMSCs during their osteogenic differentiation in vitro.
Methods
The study protocol was approved and authorized by the
Institutional Review Board according to the Helsinki
Declaration. Informed consent was obtained from all pa-
tients before surgery. During elective surgery, bone mar-
row was harvested from the iliac crest (to fill osseous
defects) or the femoral head (during elective hip-
arthroplasty) of nine (five male, four female) patients
aged 32 (±7) years. None of the patients had a history of
bone marrow pathologies.
MSC isolation and expansion
Bone marrow was filtered through 100 μm cell strainers
(BD Biosciences) to separate cells from bone particles.
Mononuclear cells were separated by density gradient
centrifugation (Biocoll 1.077 g/ml, Biochrom) and washed
with PBS. Erythrocytes were lysed using cold ammonium
chloride solution. After counting the cells were seeded in
growth medium (DMEM low glucose [Sigma-Aldrich], 20 %
FBS Superior [Biochrom], 1 % penicillin/streptomycin/
L-glutamine [Sigma-Aldrich]) in a humidified atmosphere
at 37 °C and 5 % CO2. After 1 week, non-adherent cells
were removed and growth medium changed every 3–4
days. Plastic-adherent mesenchymal stromal cells (MSC)
were passaged weekly and seeded at 5000 cells/cm2. To
fulfil the criteria of the International Society for Cellular
Therapy and to exclude contamination of MSC cultures
by hematopoietic cells MSC were analysed for a ≥95 % ex-
pression of CD73, CD90, CD105 while lacking CD34 and
CD45, (method description below) and all experiments
were carried out using MSCs derived from passage 3.
Osteogenic differentiation
For osteogenic differentiation the hMSCs were seeded in
12-well plates (3.9 cm2 per well) or tissue culture flasks
(75 cm2 per flask, both Greiner Bio-One) at 4000 cells/
cm2 and cultured for 7, 14 and 21 days in differentiation
medium (growth medium with 100 nM dexamethasone,
50 μM ascorbic acid and 20 mM β-glycerol phosphate;
all Sigma-Aldrich) with medium changed twice weekly.
For each time point there were flasks and wells with
three different concentrations of Rivaroxaban (20, 100,
500 ng/ml) and Enoxaparin (2, 10, 50 μg/ml) spanning
the median serum concentrations measured in former
studies [12–14] as well as negative controls containing
0.1 % DMSO in which Rivaroxaban had to be solved or
PBS, respectively.
Cell count
After 7, 14 and 21 days in differentiation medium cells
were trypsinized (Trypsin-EDTA, Sigma-Aldrich) and
treated with a cell scraper (Greiner Bio-One). Cell count
and viability were determined by haemocytometer using
trypan blue exclusion and proliferation rate was calcu-
lated for each drug concentration and control flask,
respectively.
Quantitative real-time PCR
RNA was purified using RNeasy Mini Kit in combination
with RNAse-free DNase kit, cDNA was synthesized by
QuantiTect Reverse Transcription Kit according to the
manufacturer’s instructions (all Qiagen). Ct values were
measured in duplicate on a StepOne Real-Time PCR
System using the SYBR Green PCR Master Mix (both
Applied Biosystems). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) served as the reference control
and its Ct values during drug treatment are provided in
Additional file 1: Figure S1. Fold changes of mRNA
expression levels were calculated using the 2-ΔΔCt
method [15]. Each drug-treated group was compared to
its carrier control (DMSO for Rivaroxaban, PBS for
Enoxaparin). Primers for ALPL, BGLAP, BMP2, CDH11,
DKK1, RUNX2, OSX/SP7 and GAPDH were self-
designed and purchased from Biolegio (Nijmegen,
Netherlands). All other primers were QuantiTect Primer
Assays purchased from Qiagen. Detailed sequence and
purchase information is provided in Additional file 2:
Table S1.
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Flow cytometric analysis of surface receptors
Fluorescence-conjugated antibodies (unless otherwise
noted all BD Biosciences) against human CD10 (clone
HI10a), CD34 (8G12), CD45 (2D1), CD49e (IIA1), CD73
(AD2), CD90 (5E10), CD92 (VIM-15b, Acris) and
CD105 (266) as well as isotype controls (MOPC-21, 27–
35) were used for flow cytometric staining. Cells were
resuspended in Isoton® II Diluent (Beckman Coulter)
and incubated with the antibodies for 15 min at room
temperature in the dark. After 5 min fixing and washing
in 0.1 % formaldehyde (Polysciences Europe) the flow
cytometric analyses were performed using a FACSCalibur
(BD Biosciences) and data were analysed with FCS Ex-
press V3 software (De Novo Software).
Osteogenic staining
After 7, 14 and 21 days of osteogenic differentiation, re-
spectively, medium was removed from the wells and cells
were washed twice using PBS before a 5 min fixation in
4 % phosphate-buffered formaldehyde (Carl Roth). Stain-
ing of alkaline phosphatase (ALP) activity in the fixed cells
was performed using the Vector Blue Alkaline Phosphatase
Substrate Kit according to the manufacturer’s instructions
(Vector Laboratories). Calcifications were stained using
Alizarin red S (40 mM, pH 4.1, Carl Roth) for 20 min at
room temperature with constant agitation. Microscopic
images were taken using a stereomicroscope SteREO Dis-
covery.V8 with an Achromat S 0.3x FWD 236 mm object-
ive and processed using AxioVision software version 4.8.1
(all Carl Zeiss). Differentiation was quantified by measur-
ing the intensity of alkaline phosphatase-stained cells in
blue and Alizarin-stained calcified areas in red using
ImageJ software (rsbweb.nih.gov).
Statistical analyses
Statistical analyses were performed using GraphPad
Prism (version 5.01, GraphPad Software Inc., CA, USA).
Data are given as mean ± standard error of the mean
(SEM). Kolmogorov-Smirnov tests for sample distribu-
tion and Friedman one-way ANOVA for paired samples
with post-hoc Dunn’s multiple comparison were used
for statistical examination. Adjusted p-values are pro-
vided in the text, and asterisks are used throughout the
figures to indicate the levels of significance (*p < 0.05,
**p < 0.01, ***p < 0.001).
Results
Effects on osteoprogenitor cell number
During osteogenic differentiation of the MSCs of each of
the 9 donors, Enoxaparin treatment increased number of
viable hMSCs during the first week in a dose-dependent
manner (2 μg/ml: 109 %, 10 μg/ml: 121 %, 50 μg/ml:
130 %; p 0.145, 0.025, 0.002; respectively, Fig. 1). During
the second and third week of differentiation, however,
there were no measurable changes in the cell count of
Enoxaparin-treated cells. Rivaroxaban treatment had no
significant influence on the proliferation of the differenti-
ating cells at any time (Fig. 1).
Effects on osteoprogenitor mRNA expression
RT-PCR analyses of the differentiating MSCs of each of
the 9 donors showed that the expression levels of
marker genes involved in osteogenic differentiation like
alkaline phosphatase, liver/bone/kidney (ALPL), osteo-
calcin (BGLAP/OCN), bone-morphogenetic protein 2
(BMP2), Runt-related transcription factor 2 (RUNX2)
and bone-specific transcription factor Sp7, also known
as osterix (SP7/OSX), were significantly down-regulated
after 7 days of Enoxaparin treatment while Rivaroxaban-
treated cells showed no significant changes (Fig. 2). Fur-
thermore, in the Enoxaparin-treated group we measured
significantly lower expression levels of the osteoblast-
specific cadherin (CDH11) and the Wnt signaling inhibitor
Dickkopf-1 (DKK1) after 7 and 14 days of differentiation.
IGF2 and its binding protein 2 (IGFBP2) were also down-
regulated by Enoxaparin treatment after 7 days and colla-
gen type I (COL1A1) after 14 days of differentiation. The
only significant effects Rivaroxaban treatment had on the
gene expression of the tested markers was a reduction of
DDK1 on day 7 in cells treated with the highest concentra-
tion of the drug and an up-regulation of IGF2 after 14 days
of differentiation (Fig. 2).
Effects on osteoprogenitor phenotype
We further analysed the expression of several surface re-
ceptors of the MSCs of each of the 9 donors during
osteogenic differentiation by flow cytometry. Whereas
mesenchymal stromal markers CD73, CD90, CD105 and
haematopoietic markers CD34, CD45 were not altered
by treatment with either drug (data not shown), there


































Fig. 1 Effects on osteoprogenitor proliferation. Bar chart of cell
count analysis showing the Enoxaparin dose-dependent increase in
proliferation during the first week of osteogenic differentiation.
Asterisks show significance levels of Dunn’s multiple comparison
post-hoc tests to the control group (n = 9)
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shown to be highly regulated during osteogenic differenti-
ation [16]. As shown in Fig. 3 Enoxaparin treatment sig-
nificantly down-regulated the surface expression of CD92
in a dose- and time-dependent manner (day 7: 2 μg/ml:
89 %, 10 μg/ml: 84 %, 50 μg/ml: 82 %, p 0.074, 0.027,
0.038; day 14: 82, 76, 68 %, p 0.053, 0.034, 0.037, respect-
ively). The same effect was seen on CD10 expression (day
7: 89, 89, 85 %, p 0.041, 0.003, 0.001; day 14: 75, 74, 63 %,
p 0.066, 0.025, 0.009, respectively). CD49e expression was
not altered during the first week, but significantly de-
creased after 2 weeks of Enoxaparin treatment (80, 78,
74 %, p 0.059, 0.028, 0.018, respectively). Rivaroxaban had
no significant effect on the expression level of these recep-
tors during osteogenic differentiation (Fig. 3).
Effects on osteogenic differentiation capacity
Alkaline phosphatase stainings of the differentiating MSCs




































































Fig. 2 Effects on osteoprogenitor mRNA expression. Bar charts of relative mRNA expression of several osteogenic marker genes during
differentiation showing the dose- and time-dependent influence of Enoxaparin. Asterisks show significance levels of Dunn’s multiple comparison

















































ctrl 2 µg/mL E     10 µg/mL E    50 µg/mL E    20 ng/mL R    100 ng/mL R     500 ng/mL R
Fig. 3 Effects on osteoprogenitor phenotype. Bar charts of surface receptor expression during osteogenic differentiation showing the dose- and time-
dependent influence of Enoxaparin. Asterisks show significance levels of Dunn’s multiple comparison post-hoc tests to the control group (n = 9)
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no visibly detectable changes in Enoxaparin- or Rivar-
oxaban-treated cells and untreated cells and quantitative
image analysis of the stainings showed no changes in ALP
intensity at all timepoints tested (Fig. 4). The decreased
calcification capacity of Enoxaparin-treated cells shown by
Alizarin staining on day 21 was easily detectable. Quanti-
tative image analysis of the Alizarin staining data was con-
ducted after 14 and 21 days and showed a significant
reduction in calcification capacity at all Enoxaparin
concentrations after 21 days of osteogenic differenti-
ation (2 μg/ml: 67 %, 10 μg/ml: 67 %, 50 μg/ml: 65 %;
p 0.031, 0.035, 0.049; respectively) while no changes were
seen in Rivaroxaban-treated cells (Fig. 4).
Discussion
Bone healing is a complex biological process that in-
cludes the stages of inflammation, repair and remodel-
ling. The recruitment of MSCs, and their migration,
proliferation and differentiation into osteogenic cells is
essential for bone repair [17]. For postoperative clinical
use, knowledge of the (negative) impact of drugs on
bone healing is of great importance. In the context of
VTE prophylaxis, reports show that long-term therapy
with heparin and LMWH for the prevention of VTE
following major orthopaedic surgery has an adverse ef-
fect on bone, with an increase in fractures and osteopor-
osis having been reported [4–7]. However, the specific
effects of these drugs on the complex system of bone
healing remain to be clarified.
We are the first to show that Enoxaparin increased the
number of viable hMSCs during the first week of
osteogenic differentiation. The similar growth capacities
in both groups after 2 weeks of differentiation may be
due to the osteoblast-like character of the cells, as the
proliferation of mature osteoblasts is not influenced by
Enoxaparin [18–20]. Solayar et al. showed that Enoxa-
parin treatment caused the down-regulation of osteo-
blast function that was associated with reduced mRNA
expression of bone markers such as osteocalcin, Runx2
and BMP2 in mature osteoblasts [19]. Here, we show
that these genes were affected as early as the first week
of osteogenic differentiation, and that this was accom-
panied by a reduction in the gene expression of alkaline
phosphatase, bone-specific transcription factor Osterix
and the osteoblast-specific cadherin 11. Furthermore, we
found that treatment with Enoxaparin drastically re-
duced the expression level of IGF2 and its binding pro-
tein two that have been shown to play pivotal roles
during early osteogenic differentiation [21]. After 2
weeks of differentiation we found reduced expression
levels of collagen type I, which is secreted by osteoblasts
and is required for bone formation. As gene expression
data may not accurately reflect the actual phenotype of
the cell we also looked at the protein level and studied
the expression of surface markers (CD10, CD49e, CD92)
that had recently been reported to be highly regulated in
MSC differentiation towards the osteogenic lineage [16].
The peptidase CD10 is speculated to participate in
osteogenic differentiation by digestion of osteostatin,
osteogenic growth peptide and calcitonin [22]. The fi-
bronectin receptor CD49e, or integrin α5, is a key medi-
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Fig. 4 Effects on osteogenic differentiation capacity. Representative microscopic images out of 5 hMSC cultures with alkaline phosphatase
staining after 14 days and with Alizarin Red stained calcified areas after 21 days of osteogenic differentiation. Bar charts of the quantitative image
analysis of alkaline phosphatase positive cells and Alizarin Red positive calcifications showing the time-dependent influence of Enoxaparin and
Rivaroxaban on the osteogenic differentiation capacity of hMSC. Asterisks show significance levels of Dunn’s multiple comparison post-hoc tests
to the control group (n = 5)
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adhesion and survival, and was recently found to trigger
osteoblast differentiation and bone repair in vivo [21, 23,
24]. CD92 is responsible for choline uptake into the cell
which is then incorporated into phosphatidylcholine
mainly found in the lipid fraction of the calcification
front during both intramembranous and endochondral
bone formation [16]. In this study, we found for the first
time that all three markers were down-regulated by
Enoxaparin treatment in a dose- and time-dependent
manner. In addition, we found a significant decrease in
the calcification capacity of the Enoxaparin-treated dif-
ferentiated hMSCs. Interestingly, Street et al found that
bone repair in a rabbit model of fracture healing was at-
tenuated by Enoxaparin and that biomechanical testing
with torsional loading after 21 days revealed a significant
reduction in strength, stiffness and energy absorbed to
fracture [9]. In a rat model, Enoxaparin induced osteope-
nic changes and inhibition of bone formation. Further-
more, Casele et al. reported that in 16 women receiving
Enoxaparin during pregnancy, bone density was signifi-
cantly decreased at 6 months postpartum and 14 % of
the patients showed bone loss of more than 10 % [25].
Since the publication of the four RECORD studies
[3, 26–28], the use of Rivaroxaban increased to prevent
VTE after orthopaedic surgery. However, its effect on
bone healing is not yet understood in detail. A PubMed
search (June 1st, 2015) using the keywords “Rivaroxaban”
and “bone healing” found only four studies [11, 29–31] as
did a search using the keywords “Rivaroxaban” and “osteo-
blast” [11, 19, 29, 31].
However, Marsell et al. revealed that examination of
mature osteoblasts only reveals the effects during the
late stage of bone formation initiated at 3–4 weeks after
surgery [17].
Most studies focus on the effects on mature osteo-
blasts [19, 29, 31] but little is known about the initial
phase of bone healing and the effect on the early stages
in the first few weeks after surgery, which may be the
more interesting part for daily clinical routine.
Therefore, we evaluated the proliferation and differen-
tiation of hMSCs into osteoblasts during thrombopro-
phylaxis, on which there have been no studies to date.
While Gigi et al. found a Rivaroxaban dose-dependent
reduction in the DNA synthesis of mature osteoblasts,
Solayar et al. found no adverse effect on osteoblast via-
bility [19, 29]. Both groups, however, proposed a signifi-
cant influence on mature osteoblast function measured
by a reduction of alkaline phosphatase activity in
Rivaroxaban-treated osteoblasts that we, using diffe-
rentiating hMSCs, only found during the first week of
osteogenic differentiation when using the highest
concentration of each drug. Furthermore, we found the
calcification capacity of the differentiated hMSCs to be
unaffected by Rivaroxaban. In addition, Rivaroxaban
caused no down-regulation in the expression level of
osteogenic marker genes or surface protein markers dur-
ing the first 2 weeks of differentiation, but rather up-
regulated IGF2, which triggers mesenchymal stromal
osteogenic differentiation [21]. So, similar to a rat femur
fracture model that showed no effect of Rivaroxaban on
bone healing [11], in our study we were the first to show
that Rivaroxaban has no inhibitory effects on the osteo-
genic differentiation of human mesenchymal stromal
cells.
Conclusions
The present study addressed the effects of the thrombo-
prophylactic drugs Enoxaparin and Rivaroxaban on hu-
man mesenchymal stromal cells’ osteogenic differentiation
in vitro. We showed for the first time that Enoxaparin
promotes hMSC proliferation while inhibiting the expres-
sion of osteogenic marker genes and proteins as well as
calcification. Rivaroxaban, however, had no effect on
hMSCs during proliferation, osteogenic differentiation
and calcification, pointing towards a lesser effect on the
bone healing process.
To further understand the clinical relevance of the ef-
fects of VTE prophylaxis on postoperative bone healing,
long term in vivo studies are needed.
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